论文部分内容阅读
目的观察罗格列酮治疗2型糖尿病合并肾病的临床疗效。方法72例2型糖尿病合并肾病患者随机分为对照组和治疗组,对照组给予胰岛素和二甲双胍治疗,治疗组在对照组基础上合用罗格列酮,共16周。观察两组治疗前后空腹血糖(FBG)、餐后2 h血糖(2hBG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、甘油三脂(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、纤维蛋白原(Fib)定量及24 h尿白蛋白排泄率(UAER)以及肾功能改变,计算胰岛素敏感指数(ISI),分析比较各指标。结果治疗组较对照组治疗后FBG、HbA1c、LDL-C、FINS、TG、Fib水平明显降低(p<0.05),并显著降低2hBG和UAER(p<0.01),同时提高HDL-C水平和ISI(p<0.05)。结论罗格列酮治疗2型糖尿病合并肾病疗效显著。
Objective To observe the clinical effect of rosiglitazone on type 2 diabetic patients with nephropathy. Methods 72 cases of type 2 diabetic patients with nephropathy were randomly divided into control group and treatment group. The control group was treated with insulin and metformin. The treatment group was treated with rosiglitazone on the basis of control group for 16 weeks. The levels of fasting blood glucose (FBG), postprandial 2h blood glucose (2hBG), fasting insulin (FINS), HbA1c, triglyceride (TG), low density lipoprotein (LDL-C) (HDL-C), fibrinogen (Fib), UAER, and renal function were measured. Insulin sensitivity index (ISI) was calculated and compared with each index. Results Compared with the control group, the levels of FBG, HbA1c, LDL-C, FINS, TG and Fib in the treatment group were significantly decreased (p <0.05) and significantly decreased 2 hBG and UAER (p <0.01) (p <0.05). Conclusion Rosiglitazone treatment of type 2 diabetes with nephropathy significant effect.